The purpose of the trial is to assess how practical and well‑tolerated the alternate‑day iron supplement is, how consistently participants can follow the dosing schedule, and how accurately the screening tool IRON-5 can identify iron deficiency.

During the study, each girl will take the assigned tablet on alternate days for several weeks and will attend a few clinic visits where blood samples are drawn to check iron levels and related nutrients. She will also complete brief questionnaires about diet, menstrual patterns, fatigue and overall well‑being. All information collected will help determine the safety and ease of use of the supplement and the performance of the screening tool.

The purpose of this study is to find out if treating patients who have pulmonary hypertension and iron deficiency with ferric carboxymaltose improves their ability to exercise compared to those who receive placebo. The study will measure this by looking at changes in how far patients can walk in six minutes, which is a common way to check exercise ability in people with heart and lung conditions. The study will also look at other aspects such as quality of life, heart failure symptoms, and fatigue levels to see if the treatment helps patients feel better overall.

During the study, patients will be randomly assigned to receive either ferric carboxymaltose or placebo over a treatment period of up to four weeks. The study is double-blind, which means neither the patients nor the doctors will know who is receiving the actual medicine or placebo during the treatment. Patients will be followed for 24 weeks to see how well the treatment works. The study includes patients with different types of pulmonary hypertension, and all participants must have iron deficiency confirmed by blood tests before joining the study.

The main purpose of this research is to determine how effective these two iron supplements are at helping patients achieve normal blood hemoglobin levels. The study will evaluate which medication works better at improving iron levels in women who have mild to moderate anemia, a condition where there aren’t enough healthy red blood cells to carry adequate oxygen to the body’s tissues.

During this 12-week study, participants will receive either Sucrosomial Iron or Ferric Maltol as oral capsules. The study will track how well each medication helps restore normal iron levels and improve symptoms related to iron deficiency, such as fatigue. The medications will also be compared for how well patients tolerate them and whether they experience any side effects.

The purpose of the study is to see if ferric derisomaltose can help reduce the number of deaths related to heart problems and the number of times patients need to be hospitalized due to worsening heart failure. Participants in the study will be randomly assigned to receive either the iron treatment or no iron treatment. The study will monitor participants over a period of time to track their health outcomes, such as hospital visits and overall survival.

Throughout the study, researchers will collect information on various health indicators, including changes in heart failure symptoms and iron levels in the blood. The study aims to provide valuable insights into whether treating iron deficiency with ferric derisomaltose can improve the health and quality of life for people with Chronic Heart Failure.

Participants in the study will receive either the vitamin D and sucrosomial iron combination or the ferric carboxymaltose treatment. The study will last for 24 weeks, during which the effects of these treatments on heart failure symptoms will be monitored. The main focus will be on the distance participants can walk in six minutes, which is a common way to assess physical ability in heart failure patients. Other aspects, such as quality of life and heart function, will also be evaluated.

The study will help determine if the oral combination of vitamin D and sucrosomial iron is a viable alternative to the intravenous iron treatment for improving the health of patients with chronic heart failure and iron deficiency. This research could provide valuable insights into more accessible treatment options for managing these conditions.

The purpose of the study is to evaluate how the iron treatment affects the patients’ physical abilities and immune system, particularly looking at changes in the Neutrophil to Lymphocyte Ratio (NLR) and using a method called Nanostring to analyze immune responses. The study will also investigate the effects of the treatment on the tumor environment and the patients’ overall health outcomes, both in the short and long term.

Participants in the study will receive the treatment through an intravenous infusion, which means the solution is given directly into a vein. The study will monitor various health indicators, including physical capacity, immune function, and any side effects. The goal is to gather information that could help improve treatment strategies for patients with colorectal cancer who have iron deficiency.

The purpose of the study is to determine if this iron treatment can improve the quality of life and exercise capacity in patients who are undergoing a procedure called Transcatheter Aortic Valve Implantation (TAVI). TAVI is a minimally invasive procedure used to replace the narrowed aortic valve. Participants in the study will receive either the iron treatment or a placebo. Over the course of the study, participants will be monitored for changes in their quality of life, ability to exercise, and cognitive function, which refers to mental processes like thinking and memory.

The study will last for several months, during which participants will undergo various assessments, including questionnaires and a walking test, to evaluate their progress. The main goal is to see if the iron treatment can help improve the overall well-being and physical abilities of those with severe aortic stenosis and iron deficiency. The results will help determine if this treatment could be beneficial for similar patients in the future.